Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 50,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

NCT03376802
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease

NCT00739037
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

NCT00835237
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
Boostrix®, Decavac™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

NCT00647972
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine Tablets 20 mg, Zyprexa® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

NCT07269301
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

NCT04006301
View directory record Official record
Conditions
Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
JNJ-74699157
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Indena's Virtiva® Plus Ginkgo Biloba Extract on Stress, and Cognitive Performance

NCT06583941
View directory record Official record
Conditions
Stress, Mood, Cognitive Change
Interventions
Low Dose Virtiva Plus, High Dose Virtiva Plus
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
50 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

NCT03330405
View directory record Official record
Conditions
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions
Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
38
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of Acetaldehyde in the Development of Oral Cancer

NCT05973656
View directory record Official record
Conditions
Alcohol-Related Carcinoma, Fanconi Anemia, Oral Cavity Carcinoma
Interventions
Alcohol, Biospecimen Collection, Breath Test
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Early Phase 1 Interventional Results available

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779
View directory record Official record
Conditions
Alcohol Use Disorder, Severe
Interventions
Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
Drug · Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint

NCT01705496
View directory record Official record
Conditions
Prosthetic Joint Infections
Interventions
[124I]FIAU
Radiation
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

NCT00799396
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Coronary Heart Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 22, 2026, 4:13 PM EDT
Active, not recruiting Phase 1 Interventional

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

NCT05621096
View directory record Official record
Conditions
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Bridging radiation therapy, Liso-cel, Post-infusion radiation
Radiation · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 4 Interventional

Comparison of Absorption of Vitamin D in Cystic Fibrosis

NCT01880346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vitamin D Powder, Vitamin D Oil
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646
View directory record Official record
Conditions
Endometriosis
Interventions
OG-6219, Placebo
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

NCT00278161
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Pegfilgrastim, Rituximab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02057770
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
busulfan, fludarabine phosphate, total-body irradiation (TBI), Stem cell transplant, cyclophosphamide, tocilizumab
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 22, 2026, 4:13 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

NCT01093170
View directory record Official record
Conditions
Geographic Atrophy
Interventions
RNA-144101
Drug
Lead sponsor
Mark Kleinman
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

NCT05917470
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONCT-534
Drug
Lead sponsor
Oncternal Therapeutics, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control

NCT03528369
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
CGS-200-1, CGS-200-5, CGS-200 Vehicle
Drug
Lead sponsor
Propella Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

NCT00891241
View directory record Official record
Conditions
Heart Failure
Interventions
LMI 1195-101
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 22, 2026, 4:13 PM EDT